Modeling therapeutic strategies in rheumatoid arthritis: Use of decision analysis and Markov models

Journal of Rheumatology

Volumn 27, Issue 3, 2000, Pages 644-652

  Albert, Daniel A ^a,b   Aksentijevich, Sofia ^a   Hurst, Stacey ^a   Fries, James F ^a   Wolfe, Frederick ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Decision analysis; Disease modifying antirheumatic drug; Markov model; Pyramid; Rheumatoid arthritis; Treatment strategies

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ARTICLE; CONTROLLED STUDY; DECISION THEORY; DRUG EFFECT; MEDICAL DECISION MAKING; MODEL; PRIORITY JOURNAL; PROBABILITY; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; DECISION SUPPORT TECHNIQUES; DECISION TREES; HUMANS; MARKOV CHAINS;

EID: 0034101656     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis. Arthritis Rheum 1993;36:729-40.
2. Hawley DJ, Wolfe F. Are the results of controlled clinical trials and observational studies of second line drug therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies. J Rheumatol 1991;18:1008-14.
3. Ward MM, Leigh JP. Pooled time series regression analysis in longitudinal studies. J Clin Epidemiol 1993;46:645-59.
4. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990;33:1449-61.
5. Felson DT, Anderson JJ, Meenan RF. Use of short term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992;35:1117-29.
6. Gotzsche PC, Podenphant J, Olesen M, Halbert P. Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. J Clin Epidemiol 1992;45:587-94.
7. ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996;347:347-52.
8. Fries JF. Re-evaluating the therapeutic approach to rheumatoid arthritis: the "sawtooth" strategy. J Rheumatol 1990;22 Suppl 17:12-5.
9. Mottonen T, Paimela L, Ahonen J, Helve T, Hannonen P, Leirisalo-Repo M. Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy. Arthritis Rheum 1996;39:996-1005.
10. Hansen TM, Kryger P, Elling H, et al. Double blind placebo controlled trial of pulse treatment with methylprednisolone combined with disease modifying drugs in rheumatoid arthritis. BMJ 1990;301:268-70.
11. Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994;330:1368-75.
12. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second-line drugs and prednisone. J Rheumatol 1992;19:1885-94.
13. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
14. van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective follow up of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26-34.
15. Borigini MJ, Paulus HE. Innovative treatment approaches for rheumatoid arthritis. Combination therapy. Baillieres Clin Rheumatol 1995;9:689-710.
16. Egsmose C, Lund B, Borg G, et al. Patients with rheumatoid arthritis benefit from early 2nd line drug therapy. 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995;22:2208-13.
17. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996;39:616-22.
18. van der Heijde DM. The effectiveness of early treatment with "second line" antirheumatic drugs: a randomized controlled trial. Ann Intern Med 1996;124:699-707.
19. Fries JF, Spitz PW, Williams CA, Block DA, Singh G, Hubert HB. A toxicity index for comparison of side effects among different drugs. Arthritis Rheum 1990;33:121-30.
20. McCarty DJ, Carerra GF. Intractable rheumatoid arthritis: treatment with combined cyclophosphamide, azathioprine, and hydroxychloroquine. JAMA 1982;248:1718-23.
21. Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 1994;37:1487-91.
22. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
23. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulphasalazine and hydroxychloroquine or a combination of all three medications. N Engl J Med 1996;334:1287-91.
24. Williams HJ, Ward JR, Reading JC, et al. Comparison of auranofin, methotrexate and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1992;35:259-69.
25. Pincus T. Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988;41:1037-41.
26. Albert DA. Decision theory in medicine: a review and critique. Milbank Mem Fund Quart 1978;56:362-401.
27. Kassirer JP, Moskowitz AM, Lau J, Pauker SG. Decision analysis: a progress report. Ann Intern Med 1987;106:275-91.
28. Pauker SG, Kassirer JP. Decision analysis. N Engl J Med 1987;316:250-8.
29. Silverstein MD, Albert DA, Hadler NM, Ropes MW. Prognosis in SLE: comparison of Markov model to life table analysis. J Clin Epidemiol 1988;41:623-33.
30. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-8.
31. Detsky AS, Naglie G, Krahn MD, Naimark D, Redelmeier DA. Primer on medical decision analysis: Part 1 - Getting started. Med Decis Making 1997;17:123-5.
32. Wilske KR, Healy LA. Remodeling the pyramid - a concept whose time has come [editorial]. J Rheumatol 1989;16:565-7.
33. Wilke WS, Clough JD. Therapy for rheumatoid arthritis: combinations of disease modifying drugs and new paradigms of treatment. Semin Arthritis Rheum 1991;21, 2 Suppl 1:21-34.
34. Wolfe F, Albert DA, Pincus T. A survey of United States rheumatologists concerning effectiveness of disease modifying antirheumatic drugs and prednisone in the treatment of rheumatoid arthritis. Arthritis Care Res 1998;11:375-80.
35. Wijnands MJH, van't Hof MA, van Leeuwen MA, van Rijswijk MH, van de Putte LBA, van Riel PLCM. Long-term second-line treatment: a prospective drug survival study. Br J Rheumatol 1992;31:253-8.
36. Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991;18:188-94.
37. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-15.
38. Fries JF, Williams CA, Singh G, Ramay DR. Response to therapy in rheumatoid arthritis is influenced by immediately prior therapy. J Rheumatol 1997;24:838-44.